NeoGenomics, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This filing reports annual results; it does not provide a clear standalone fourth-quarter financial summary. NeoGenomics operates cancer-focused clinical testing laboratories and pharmaceutical research services. Clinical Services generated 83% of 2021 revenue; Pharma Services generated 17%.
Key financial results
| Metric | FY2021 | FY2020 | Change / context |
|---|---|---|---|
| Revenue | $484.3 million | $444.4 million | Up 9.0% |
| Clinical Services revenue | $404.2 million | $382.3 million | Up 5.7% |
| Pharma Services revenue | $80.2 million | $62.1 million | Up 29.1% |
| Gross profit / margin | $187.1 million / 38.6% | $185.9 million / 41.8% | Margin down 3.2 percentage points |
| Operating loss | $118.8 million | $14.0 million | Higher operating expenses, including acquisition-related costs and stock compensation |
| Net income (loss) | $(8.3) million; $(0.07) per diluted share | $4.2 million; $0.04 per diluted share | Reported results include a $109.3 million acquisition-related gain in 2021 |
| Adjusted EBITDA (non-GAAP) | $(4.2) million | $34.8 million | Margin of (0.9)% versus 7.8% |
| Cash from operations | $(26.7) million | $1.5 million | Operating cash flow declined |
| Cash and marketable securities | $316.8 million cash; $198.6 million securities | $228.7 million cash; $67.5 million securities | $515.4 million combined at year-end 2021 |
| Debt | $532.5 million long-term debt, net; $546.3 million face value of convertible notes | $169.1 million long-term debt, net | Includes 2025 and 2028 convertible notes |
Material changes and unusual items
- Revenue growth reflected higher non-COVID clinical testing and Pharma research and informatics work. Clinical revenue included $1.6 million of COVID-19 PCR testing in 2021, versus $27.8 million in 2020; the company decided to exit that testing in Q1 2021.
- Gross margin declined partly due to acquired Inivata technology amortization, $5.3 million of COVID-19 testing inventory write-offs, and the fixed-cost structure of laboratories. Operating expenses rose substantially, including acquisition and integration costs, increased research and development, higher stock-based compensation, and an $11.2 million regulatory-matter reserve.
- Inivata, acquired in June, added liquid-biopsy and minimal-residual-disease capabilities; Trapelo, acquired in April, added a precision-oncology decision-support platform. Acquisitions used $419.4 million of net cash. The Inivata remeasurement and related items generated the $109.3 million gain, which materially affected reported net loss.
- Pharma contract backlog reached approximately $267 million, up from $209 million at year-end 2020. Management cautions that substantially all backlog is subject to cancellation provisions.
- Financing provided $725.3 million of cash, including equity proceeds and $334.4 million net proceeds from the 2028 convertible notes. Working capital was $594.3 million at year-end.
Outlook, risks, and contingencies
- Management said cash, marketable securities, and expected collections should fund near-term operating and capital needs for at least 12 months. Planned 2022 capital expenditures were $25–$35 million. The filing does not provide a numerical 2022 revenue or earnings forecast.
- 2022 priorities include launching tests and securing reimbursement, growing revenue and profitability, meeting turnaround-time targets, and designing a next-generation laboratory information system. Management did not anticipate significant 2022 clinical revenue changes from known legislative changes.
- The company voluntarily notified HHS’s Office of Inspector General in November 2021 about an internal investigation into certain consulting and service agreements and healthcare-law compliance. It accrued $11.2 million as its best estimate of the minimum probable loss; it could not estimate a range of possible additional losses. Further penalties, repayment, or operating restrictions could be material.
- Inivata subsidiaries face a patent-infringement lawsuit filed by Natera concerning the InVisionFirst-Lung test. The company said the matter was in the pleadings stage; its outcome was not estimable or probable at filing.
- Key risks include COVID-related volume volatility, payer coverage and reimbursement changes, proposed or evolving regulation of laboratory-developed tests, competition and pricing, capacity and staffing constraints, cyber and privacy risks, and debt-service or conversion-related cash needs.
- Management reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions. The internal-control assessment excluded Trapelo and Inivata, which the company planned to include in its 2022 assessment.
Investor verification priorities
- Track whether core non-COVID clinical volumes and gross margin recover, and whether growth converts into positive operating cash flow and adjusted EBITDA.
- Monitor progress, reimbursement, and commercial adoption of Inivata’s liquid-biopsy tests and Trapelo’s platform; compare realized Pharma revenue with backlog and cancellations.
- Follow the OIG investigation, reserve updates, and any further disclosures about potential losses or remedial actions.
- Review convertible-note terms, dilution exposure, liquidity, and the company’s ability to meet obligations while funding acquisitions, research, and capital spending.
- Assess the impact of payer policies and any LDT regulatory changes on coverage, pricing, and test launches.